No-one is likely to forget the tragic events of 2020 and one company leading efforts to prepare for the next pandemic is Poolbeg Pharma. Optimum Strategic Communications’ Richard Staines interviewed CEO Jeremy Skillington to find the latest insights. Discussions are not about whether another pandemic will happen, but when, as a number of factors converge […]
AI analysis of unique human challenge trial data provides unparalleled insights into influenza infection Novel influenza drug targets identified faster and more cost-effectively using AI 29 June 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, announces a significant breakthrough […]
Next Generation Oral Vaccine Programme Advancing Through Non-Dilutive Funding 22 June 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with high unmet medical needs, announces an update to its Oral Vaccine Programme following the award of non-dilutive grant funding by the Irish Government’s Disruptive Technologies Innovation […]
24 May 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces the appointment of Brendan Buckley as an Independent Non-Executive Director of the Company with immediate effect. Brendan will also replace Cathal Friel as a member of the Remuneration Committee. Read more…
Significant milestones reached, well capitalised and positioned for future growth London, UK 30 March 2023 – Poolbeg Pharma Plc (AIM: POLB, OTCQB: POLBF “Poolbeg” or the “Company”) a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, is pleased to announce its audited results for the year ended 31 December 2022. Read more…
